Skip to main navigation Skip to main content Skip to footer For Medicare For Providers For Brokers For Employers Español For Individuals & Families: For Individuals & Families Medical Dental Other Supplemental Explore coverage through work How to Buy Health Insurance Types of Dental Insurance Open Enrollment vs. Special Enrollment See all topics Shop for Medicare plans Member Guide Find a Doctor Log in to myCigna
Home Knowledge Center Wellness Library sotrovimab

sotrovimab

Pronunciation: soe TROE vi mab

What is the most important information I should know about sotrovimab?

What is the most important information I should know about sotrovimab?

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

What is sotrovimab?

What is sotrovimab?

Due to the high frequency of the Omicron BA.2 sub-variant, this drug is not currently authorized in any US region; therefore, this drug may not be administered for treatment of COVID-19 under the EUA until further notice by the US FDA.

Sotrovimab is an experimental medicine being studied for use in treating conditions caused by coronavirus. It is not yet known if sotrovimab is a safe and effective treatment for any condition.

Sotrovimab is for use in adults and children at least 12 years old who weigh at least 88 pounds (40 kilograms).

The risk of COVID-19 symptoms becoming severe may be higher in people who:

  • are overweight;
  • have chronic kidney disease;
  • have diabetes;
  • have a weak immune system (caused by disease or by using certain medicine);
  • have sickle cell disease;
  • have a heart problem or high blood pressure;
  • have a neurodevelopmental disorder such as cerebral palsy;
  • have asthma or other chronic breathing disorder; or
  • have a tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19).

There also may be a higher risk of severe COVID-19 symptoms in pregnant women and in adults who are 65 and older.

Sotrovimab has not been approved to treat coronavirus or COVID-19. However, this medicine may help prevent the need for emergency medical care or admission to a hospital because of COVID-19. Sotrovimab is not authorized for use in people who are already in the hospital or receiving supplemental oxygen for COVID-19.

Sotrovimab may also be used for purposes not listed in this medication guide.

What should I discuss with my healthcare provider before receiving sotrovimab?

What should I discuss with my healthcare provider before receiving sotrovimab?

You should not use sotrovimab if you are allergic to it, or if you have ever had:

  • any serious or chronic illness;
  • any allergies; or
  • if you are pregnant or breastfeeding.

COVID-19 is more likely to cause serious illness or death in a pregnant woman. Not all risks are known yet, but being treated with sotrovimab is likely to be less harmful than being infected with COVID-19 during pregnancy.

How is sotrovimab given?

How is sotrovimab given?

Sotrovimab is usually given as only one dose as soon as possible after you test positive for COVID-19, or within 10 days after the start of symptoms.

Sotrovimab is injected into a vein by a healthcare provider.

Sotrovimab is injected slowly over 30 minutes. You will be watched for a short time to make sure you do not have an allergic reaction.

Being treated with sotrovimab will not make you less contagious to other people. Keep using infection control methods such as self-isolation, social distancing, hand-washing, using protective face covering, disinfecting surfaces you touch a lot, and not sharing personal items with others.

Sotrovimab also may not keep you from becoming infected with coronavirus again. Being treated with this medicine could also affect your body's immune response to a coronavirus vaccine. Sotrovimab are still being studied and all of their risks are not yet known.

What happens if I miss a dose?

What happens if I miss a dose?

Sotrovimab is given in a single dose and does not have a daily dosing schedule.

What happens if I overdose?

What happens if I overdose?

In a medical setting an overdose would be treated quickly.

What should I avoid while receiving sotrovimab?

What should I avoid while receiving sotrovimab?

Follow your doctor's instructions about any restrictions on food, beverages, or activity.

What are the possible side effects of sotrovimab?

What are the possible side effects of sotrovimab?

Get emergency medical help if you have signs of an allergic reaction: hives, itching; difficult breathing; swelling of your face, lips, tongue, or throat.

Some side effects may occur during or up to 24 hours after the injection. Tell your medical caregivers right away if you have:

  • throat irritation, swelling in your face or throat;
  • fast, slow, or uneven heart rate;
  • confusion, dizziness, a light-headed feeling (like you might pass out);
  • chest pain, wheezing, shortness of breath;
  • fever, chills, sweating, nausea, weakness, tiredness;
  • pounding in your neck or ears;
  • rash, itching; or
  • headache, muscle pain.

Call your doctor if you have new or worsening symptoms after the infusion, such as fever, confusion, weakness, tiredness, trouble breathing, or fast or slow heartbeats.

Common side effects may include:

  • diarrhea; or
  • rash.

Not all possible side effects are known.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect sotrovimab?

What other drugs will affect sotrovimab?

Other drugs may affect sotrovimab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Where can I get more information?

Where can I get more information?

Your doctor or pharmacist can provide more information about sotrovimab.

This information does not replace the advice of a doctor. Healthwise, Incorporated, disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. Learn how we develop our content.

Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.

<cipublic-spinner variant="large"><span>Loading…</span></cipublic-spinner>

Page Footer

I want to...

Get an ID card File a claim View my claims and EOBs Check coverage under my plan See prescription drug list Find an in-network doctor, dentist, or facility Find a form Find 1095-B tax form information View the Cigna Glossary Contact Cigna

Audiences

Individuals and Families Medicare Employers Brokers Providers

Secure Member Sites

myCigna member portal Health Care Provider portal Cigna for Employers Client Resource Portal Cigna for Brokers

Cigna Company Information

About Cigna Company Profile Careers Newsroom Investors Suppliers Third Party Administrators International Evernorth

 Cigna. All rights reserved.

Privacy Legal Product Disclosures Cigna Company Names Customer Rights Accessibility Non-Discrimination Notice [PDF] Language Assistance [PDF] Report Fraud Sitemap

Disclaimer

Individual and family medical and dental insurance plans are insured by Cigna Health and Life Insurance Company (CHLIC), Cigna HealthCare of Arizona, Inc., Cigna HealthCare of Illinois, Inc., and Cigna HealthCare of North Carolina, Inc. Group health insurance and health benefit plans are insured or administered by CHLIC, Connecticut General Life Insurance Company (CGLIC), or their affiliates (see a listing of the legal entities  that insure or administer group HMO, dental HMO, and other products or services in your state). Accidental Injury, Critical Illness, and Hospital Care plans or insurance policies are distributed exclusively by or through operating subsidiaries of Cigna Corporation, are administered by Cigna Health and Life Insurance Company, and are insured by either (i) Cigna Health and Life Insurance Company (Bloomfield, CT); (ii) Life Insurance Company of North America (“LINA”) (Philadelphia, PA); or (iii) New York Life Group Insurance Company of NY (“NYLGICNY”) (New York, NY), formerly known as Cigna Life Insurance Company of New York. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. LINA and NYLGICNY are not affiliates of Cigna.

All insurance policies and group benefit plans contain exclusions and limitations. For availability, costs and complete details of coverage, contact a licensed agent or Cigna sales representative. This website is not intended for residents of New Mexico.

Selecting these links will take you away from Cigna.com to another website, which may be a non-Cigna website. Cigna may not control the content or links of non-Cigna websites. Details